FDA and EMA chief med­ical of­fi­cers don’t ex­pect Chat­G­PT to help with drug re­views any­time soon

BOSTON — The myr­i­ad us­es of Chat­G­PT and oth­er large lan­guage mod­els have spread like wild­fire, but the two chief med­ical of­fi­cers at the US Food and Drug Ad­min­is­tra­tion and the Eu­ro­pean Med­i­cines Agency said yes­ter­day that they aren’t about to start us­ing the new tech to speed up drug re­views.

“I have one big con­cern and that’s garbage in, garbage out,” Stef­fen Thirstrup, CMO of EMA, told at­ten­dees at the Drug In­for­ma­tion As­so­ci­a­tion an­nu­al con­fer­ence on Thurs­day. “These mod­els on­ly pick up what’s been pub­lished. That’s the tip of the ice­berg.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER